654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study

Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian C. Anderson, Giuseppe Curigliano, M.J. De Miguel Luken, Mamta Kalra, D-Y. Oh, J.O. Park, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Aaron Smith, K. K. Machado, C. Saura Manich